JP2010540657A5 - - Google Patents

Download PDF

Info

Publication number
JP2010540657A5
JP2010540657A5 JP2010528161A JP2010528161A JP2010540657A5 JP 2010540657 A5 JP2010540657 A5 JP 2010540657A5 JP 2010528161 A JP2010528161 A JP 2010528161A JP 2010528161 A JP2010528161 A JP 2010528161A JP 2010540657 A5 JP2010540657 A5 JP 2010540657A5
Authority
JP
Japan
Prior art keywords
patient
antigen
antibody
psma
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010528161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540657A (ja
JP5951929B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/078742 external-priority patent/WO2009046294A2/en
Publication of JP2010540657A publication Critical patent/JP2010540657A/ja
Publication of JP2010540657A5 publication Critical patent/JP2010540657A5/ja
Application granted granted Critical
Publication of JP5951929B2 publication Critical patent/JP5951929B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010528161A 2007-10-03 2008-10-03 Ｐｓｍａ抗体を用いる増殖性障害の治療 Active JP5951929B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97736407P 2007-10-03 2007-10-03
US60/977,364 2007-10-03
PCT/US2008/078742 WO2009046294A2 (en) 2007-10-03 2008-10-03 Treatment of proliferative disorders using antibodies to psma

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013207386A Division JP5969446B2 (ja) 2007-10-03 2013-10-02 Ｐｓｍａ抗体を用いる増殖性障害の治療
JP2016005363A Division JP6054557B2 (ja) 2007-10-03 2016-01-14 Ｐｓｍａ抗体を用いる増殖性障害の治療

Publications (3)

Publication Number Publication Date
JP2010540657A JP2010540657A (ja) 2010-12-24
JP2010540657A5 true JP2010540657A5 (enExample) 2011-11-24
JP5951929B2 JP5951929B2 (ja) 2016-07-13

Family

ID=40404317

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010528161A Active JP5951929B2 (ja) 2007-10-03 2008-10-03 Ｐｓｍａ抗体を用いる増殖性障害の治療
JP2013207386A Active JP5969446B2 (ja) 2007-10-03 2013-10-02 Ｐｓｍａ抗体を用いる増殖性障害の治療
JP2016005363A Active JP6054557B2 (ja) 2007-10-03 2016-01-14 Ｐｓｍａ抗体を用いる増殖性障害の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013207386A Active JP5969446B2 (ja) 2007-10-03 2013-10-02 Ｐｓｍａ抗体を用いる増殖性障害の治療
JP2016005363A Active JP6054557B2 (ja) 2007-10-03 2016-01-14 Ｐｓｍａ抗体を用いる増殖性障害の治療

Country Status (5)

Country Link
US (4) US20100291113A1 (enExample)
EP (3) EP2209498A2 (enExample)
JP (3) JP5951929B2 (enExample)
CA (1) CA2700410C (enExample)
WO (1) WO2009046294A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010249719A1 (en) 2009-05-19 2012-05-31 Aic Blab Company Composite current collector and methods therefor
US20130225541A1 (en) * 2012-02-24 2013-08-29 Cornell University Elevated PSMA Identifies Lethal Prostate Cancers
HK1202256A1 (en) * 2012-02-28 2015-09-25 Cornell University Psma as a biomarker for androgen activity in prostate cancer
JP6340006B2 (ja) * 2012-10-05 2018-06-06 コーネル ユニヴァーシティー アンドロゲン抑制、前立腺特異的膜抗原、および条件的に増大した脆弱性の概念
MA41046A (fr) * 2014-10-10 2017-08-15 Memorial Sloan Kettering Cancer Center Thérapies liées au psma
WO2016130819A2 (en) * 2015-02-11 2016-08-18 Emergent Product Development Seattle Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
US12508271B2 (en) 2017-04-11 2025-12-30 The Johns Hopkins University Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer imaging or radiotherapy
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
WO2021076546A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
EP4146805A2 (en) * 2020-05-05 2023-03-15 ARO Biotherapeutics Company Prostate specific membrane antigen binding fibronectin type iii domains and cells comprising the same
IL299748A (en) 2020-07-08 2023-03-01 Lava Therapeutics N V Antibodies that bind PSMA and T gamma delta receptors
IL307582A (en) 2021-04-14 2023-12-01 Aro Biotherapeutics Company CD71-binding domains of the fibronectin type
US12239710B2 (en) 2021-04-14 2025-03-04 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5869053A (en) * 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US6010902A (en) * 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6197298B1 (en) * 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
DE4140142A1 (de) * 1991-12-05 1993-06-09 Boehringer Mannheim Gmbh, 6800 Mannheim, De Multivalentes dextranreagenz zum einsatz in praezipitationstests
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
DE69327229T2 (de) * 1992-12-11 2000-03-30 The Dow Chemical Co., Midland Multivalente einkettige Antikörper
US5861156A (en) * 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
US5705614A (en) * 1993-04-09 1998-01-06 Chiron Corporation Methods of producing antigen forks
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
US6569432B1 (en) * 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
WO1996026272A1 (en) * 1995-02-24 1996-08-29 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
GB9504344D0 (en) * 1995-03-03 1995-04-19 Unilever Plc Antibody fragment production
US5747035A (en) * 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6150508A (en) 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
AU6914098A (en) * 1997-04-03 1998-10-30 Universite Laval Transgenic expression in genital tract and sexual accessory glands
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO1999002567A2 (en) * 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6030792A (en) * 1997-11-13 2000-02-29 Pfizer Inc Assays for measurement of protein fragments in biological media
US5981209A (en) 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6709844B1 (en) * 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
AU3657899A (en) * 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6200765B1 (en) * 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
US6833438B1 (en) * 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) * 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
AU757698C (en) * 1998-06-01 2004-04-08 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US6361774B1 (en) * 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
DE60039354D1 (de) * 1999-04-09 2008-08-14 Univ Zuerich Verfahren zur Stabilisierung von chimären Immunoglobulinen oder Immunoglobulinfragmenten und stabilisiertes Anti-EGP-2-scFv-Fragment
IL145941A (en) * 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
US6342587B1 (en) * 1999-10-22 2002-01-29 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products and uses thereof
ES2276708T3 (es) * 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
WO2001071005A2 (en) * 2000-03-24 2001-09-27 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
AU2001247616B2 (en) * 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US6375991B1 (en) * 2000-09-08 2002-04-23 Albemarle Corporation Production of concentrated biocidal solutions
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
US6884907B2 (en) 2001-05-11 2005-04-26 Guilford Pharmaceuticals Inc. Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
JP4619651B2 (ja) * 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
AU2002336446B2 (en) * 2001-09-06 2008-03-06 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7494646B2 (en) * 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
IL159422A0 (en) * 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
EP2360169B1 (en) * 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
KR100988949B1 (ko) * 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040018519A1 (en) * 2001-11-16 2004-01-29 Wright ,Jr. George L Methods and devices for quantitative detection of prostate specific membrane antigen and other prostatic markers
CA2473144C (en) * 2002-02-05 2013-05-28 Genentech, Inc. Protein purification
DK1501369T3 (en) * 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
JP2004000045A (ja) * 2002-05-31 2004-01-08 Kyowa Hakko Kogyo Co Ltd 前立腺特異的膜抗原に対する抗体
EP2365004B1 (en) * 2002-06-21 2016-01-06 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers
US20050026178A1 (en) * 2003-03-28 2005-02-03 Marit Nilsen-Hamilton Allosteric probes and methods
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
HUE029951T2 (en) * 2003-07-28 2017-04-28 Genentech Inc Reduction of Protein A Dissolution in Protein A Affinity Chromatography
US7524813B2 (en) * 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
ZA200601699B (en) * 2003-10-16 2007-05-30 Micromet Ag Multispecific deimmunized CD3-binders
EP3434275A1 (en) * 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
EP1704228B1 (en) * 2004-01-16 2012-04-11 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immunokinases
EP1718667B1 (en) * 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2005101017A1 (en) * 2004-04-07 2005-10-27 Genentech, Inc. Mass spectrometry of antibody conjugates
NZ550816A (en) * 2004-04-22 2009-12-24 Agensys Inc Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EA010374B1 (ru) * 2004-07-16 2008-08-29 Микромет Аг Полипептиды с повышенной экспрессией
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2579805T3 (es) * 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
CN101160324B (zh) * 2005-02-18 2013-04-24 米德列斯公司 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
EP2295080A3 (en) * 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2682605A1 (en) * 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
US7867483B2 (en) * 2007-10-18 2011-01-11 Bn Immunotherapeutics, Inc. Use of MVA to treat prostate cancer
US8742076B2 (en) * 2008-02-01 2014-06-03 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
WO2010009124A2 (en) * 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
AU2009288561B2 (en) * 2008-09-08 2014-07-24 Conocophillips Company System for incondensable component separation in a liquefied natural gas facility
CN102308004A (zh) * 2008-10-30 2012-01-04 卡里斯生命科学卢森堡控股有限责任公司 评价rna图案的方法
CA2743211A1 (en) * 2008-11-12 2010-05-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods and systems of using exosomes for determining phenotypes
SG171764A1 (en) * 2008-12-16 2011-07-28 Millipore Corp Purification of proteins
CN102265059B (zh) * 2008-12-25 2013-08-07 东海橡塑工业株式会社 流体封入式隔振装置
AU2010245011B2 (en) * 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011003171A1 (en) * 2009-07-08 2011-01-13 Smart Technologies Ulc Three-dimensional widget manipulation on a multi-touch panel
TWM383852U (en) * 2009-07-13 2010-07-01 Speedtech Corp An improvement of the universal serial bus connector
EP2471556A4 (en) * 2009-10-05 2015-06-03 Canon Kk CONTRASTANT FOR PHOTOACUSTIC IMAGING AND PROCESS FOR PHOTOACUSTIC IMAGING THEREWITH

Similar Documents

Publication Publication Date Title
Ratziu et al. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
Forte et al. Obesity, diabetes, the cardiorenal syndrome, and risk for cancer
Saleh et al. Ibuprofen suppresses depressive like behavior induced by BCG inoculation in mice: role of nitric oxide and prostaglandin
JP2010515774A5 (enExample)
Zhang et al. Apelin attenuates depressive-like behavior and neuroinflammation in rats co-treated with chronic stress and lipopolysaccharide
RU2587053C2 (ru) Комбинированная терапия и способ оценки невосприимчивости к лечению
CN116459250A (zh) 检测和治疗生长激素缺乏症
Paderni et al. Controlled delivery of naltrexone by an intraoral device: in vivo study on human subjects
Liu et al. AS-IV enhances the antitumor effects of propofol in NSCLC cells by inhibiting autophagy
Tang et al. Tetrahydroberberrubine exhibits preventive effect on obesity by activating PGC1α-mediated thermogenesis in white and brown adipose tissue
WO2012044783A8 (en) Method of achieving a thymosin beta 4 concentration in a human patient
Tiwari et al. Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats
Chawes et al. Pharmacokinetic comparison of inhaled fixed combination vs. the free combination of beclomethasone and formoterol p MDI s in asthmatic children
Huo et al. Ultrasound‐Guided Capsular Thyroid Injection Therapy With Dexamethasone and Lidocaine Mixture for Subacute Thyroiditis: A Single‐Center Study
Veldsman et al. Combined intravenous bolus amino acid supplementation and mobilization on early muscle loss in critically ill adults: A randomized controlled trial
CN117327067A (zh) 一种小分子化合物epic-1042、药物组合物及其制备方法和应用
JP2010510495A5 (enExample)
Egan et al. A randomized, single-blind, pharmacokinetic and doseresponse study of subcutaneous methotrexate, 15 and 25 MG/week, for refractory ulcerative colitis and Crohn's Disease
Thynne et al. A dose of paracetamol for the levothyroxine absorption test
Kodama et al. Four problems with the clinical control of interstitial pneumonia, or chronic fatigue syndrome, using the megadose vitamin C infusion system with dehydroepiandrosterone-cortisol annex
CN115837042B (zh) 当归补血汤在制备增强免疫检查点抑制剂疗效的药物中的应用
Gupta et al. Evidence based clinical study to assess the usefulness of homoeopathic medicines in patients of benign prostatic hyperplasia
Buch Clinically oriented pharmacology
Sommer et al. 118 Curing erectile dysfunction—long term effects of taking PDE-5-inhibitors on a daily basis
Blaker Neurotoxic Interactions Between Methamphetamine and Alcohol Drinking